Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, across generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN) and ...

Regeneron's Phase III trial investigated cemdisiran and pozelimab as both monotherapies and in combination in gMG.

Discover practical, expert-recommended home modifications that can help reduce fatigue and prevent injury in people living ...

Don't let myasthenia gravis keep you from exploring. Learn expert tips on managing fatigue, choosing accessible lodging, ...

James F. Howard Jr., MD, discusses addressing long-standing gaps in seronegative disease care with efgartigimod.

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular condition that causes muscle weakness and severe fatigue. The fatigue associated with MG is often described as “fatigable weakness,” ...

A myasthenic crisis is a life-threatening complication of myasthenia gravis. It’s when the muscles that you use to breathe get so weak that you can’t get air in and out of your lungs. It isn’t the ...

Now that Alexion’s Soliris is in AstraZeneca's hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog ...

Johnson & Johnson (NYSE: JNJ) today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY® ...

Myasthenia gravis is a rare neuromuscular disease in which the voluntary muscles quickly become tired and weak as a result of dysfunction with nerve and muscle communication. Myasthenia gravis (MG) is ...

The FDA has granted Priority Review to cemdisiran, a subcutaneously administered siRNA targeting C5 for anti-AChR antibody-positive generalized myasthenia gravis.